Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994307 | 0.88 | USP2 (0.47) | ALDH1A1CYP2C19MAPK1CYP3A4HIF1A | |
| SCHEMBL20669275 | 0.87 | TSHR (0.49) | ALDH1A1CYP2C19MAPK1OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL29172907 | 0.86 | USP2 (0.46) | ALDH1A1CYP2C19MAPK1CYP3A4HIF1A | |
| SCHEMBL8169386 | 0.84 | HSD17B10 (0.56) | ALDH1A1CYP2C19MAPK1CYP3A4HIF1A | |
| SCHEMBL26832959 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP2C19MAPK1OPRM1OPRL1 | |
| SCHEMBL5986519 | 0.83 | OPRM1 (0.54) | ALDH1A1CYP2C19MAPK1OPRM1OPRL1 | |
| SCHEMBL2593681 | 0.83 | SMN1; SMN2 (0.45) | ALDH1A1CYP2C19MAPK1CYP3A4HIF1A | |
| SCHEMBL8170293 | 0.82 | CYP1A2 (0.51) | ALDH1A1CYP2C19MAPK1OPRM1OPRL1 | |
| SCHEMBL19971641 | 0.82 | HSD17B10 (0.42) | ALDH1A1CYP2C19MAPK1CYP3A4USP2 | |
| Hydrochloric Acid SCHEMBL16454452 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1CYP2C19MAPK1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| WO-2024134466-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-27 | — | — | WO | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| EP-3656782-B1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2021-12-22 | — | — | EP | disclosed |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013832-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3656782-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019015644-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | ALDH1A1 4630/4885CYP2C19 4349/4885MAPK1 3592/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | ALDH1A1 4630/4885CYP2C19 4349/4885MAPK1 3592/4885 |
| US-20200172573-A1 | PEPTIDE AMIDE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREOF | VIP, NPPA, GRPR | ALDH1A1 3909/4885CYP2C19 320/4885MAPK1 1903/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | ALDH1A1 4322/4885CYP2C19 1164/4885MAPK1 30/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | ALDH1A1 3647/4885CYP2C19 2761/4885MAPK1 1455/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | ALDH1A1 382/4885CYP2C19 118/4885MAPK1 1245/4885 |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | VIP, NPPA, GRPR | ALDH1A1 3909/4885CYP2C19 320/4885MAPK1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.